Innovative research to facilitate women’s health

Invent Medic develops and offers research-based products that contribute to more freedom, joy and an active lifestyle.
Read more about Invent MedicRead about Efemia

Interim report Q1, 2020

“In Q1, Efemia was approved for cost coverage in Norway and the Netherlands”

Annual report for 2019

“2019 was characterised by a commercial breakthrough for Efemia”

Press release May 6, 2020

“Efemia approved for prescription with cost coverage in England”

After the launches in the UK, Germany and Norway in Q4 2019 and in Belgium and the Netherlands in Q1 2020, Efemia will be available in markets with more than 8 million potential users. We will then plan a launch in the United States at the same time as we develop/evaluate additional products.

Karin Bryder

CEO, Invent Medic Sweden

Q1 2020

Forecast: Potential Efemia users

  • 2018 – 0.5 million (swe)
  • 2019 – 8 million (+dan, ger, uk, nor)
  • 2020 – 15 million (+ned, bel and more eu countries)
  • 2021 – 35 million (+the us and additional countries)

The forecast is based on Invent Medic’s expansion plans and an estimation of women with bothersome SUI in each market. In studies, around 70% of the participants have stated that they see themselves continue to use Efemia.